Valeo Foods Group Acquires Freddi Dolciaria S.p.A, Enhancing its Position in the Italian Bakery Sector
2.5.2025 10:00:00 CEST | Business Wire | Press Release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the Italian sweet bakery producer Freddi Dolciaria S.p.A (“Freddi”), accelerating growth in South-West European region and enhancing its position in the bakery sector.
Freddi is an Italian sweet bakery company founded in 1949 by Luigi Freddi and headquartered in Castiglione delle Stiviere, Italy. Specialising in sponge cakes, Freddi has an established presence in both the Italian retail and international markets, with an annual turnover approaching €20 million and 48 employees.
This acquisition strengthens Valeo Foods Group’s position in the packaged wafers, cakes, and biscuits category, complementing the existing Balconi business across Southern Europe and international markets. The integration of Freddi is expected to drive sustainable, profitable growth while enhancing production capacity and operational efficiency. It also reinforces Valeo’s continued expansion in the region, following the acquisitions of Balconi in 2015, Val D’Enza in 2017, IDP Pattini in 2023, and Dal Colle in 2025.
Ronald Kers, CEO of Valeo Foods Group, commented: “Freddi Dolciaria is a fantastic addition to the Valeo Foods portfolio, which already includes some of Europe’s most established and beloved cakes. Commercially, this move strengthens and broadens our product range, introducing exclusive, global licencing partnerships with leading CPGs and expanding our healthy and ‘free-from’ offerings.
As Freddi Dolciaria joins our portfolio, we enhance our manufacturing and logistical capabilities, adding an additional, well invested, flexible facility to support our ambitious growth plans. This marks the next step in our vision to establish Valeo Foods as the leading European champion in sweet treats.”
Alberto Alfieri, CEO Valeo Foods, South-West Europe, added: “Freddi Dolciaria has a strong legacy of producing high-quality products that consumers love. Its product range and operational footprint align perfectly with Valeo Foods. We are delighted to welcome our 48 new colleagues to the Valeo Foods. Together, we will bring Freddi Dolciaria’s exceptional products to an even wider audience and accelerate the growth of our South-West European business.”
About Freddi Dolciaria
Freddi Dolciaria S.p.A. is an Italian sweet bakery company, founded in 1949 by Luigi Freddi in Castiglione delle Stiviere, Lombardy, Italy. With over 75 years of heritage, Freddi has built a strong reputation for producing high-quality sponge cakes, catering to both domestic and international markets. The company specialises in a diverse range of pre-packaged sponge cakes and Swiss rolls, offering a variety of products, including classic, filled, and layered cakes, as well as innovative lines designed for different consumer preferences, such as free-from and health-conscious options. Freddi generates an annual turnover approaching €20 million and employs 48 people.
About Valeo Foods Group
Valeo Foods Group is one of Europe’s fastest-growing food companies, specialising in sweets, snacks, and treats. Home to over 90 brands including Balconi cakes and wafers, Pedro confectionary, Mila, Lina and Horalky wafers, Rowse Honey, Bernard maple syrup, Barratt’s sweets, Fox’s mints and Kettle Chips. We operate in over 100 countries serving major retailers, discounters, e-commerce, convenience stores, wholesalers, and foodservice operators. With revenues exceeding €1.8 billion, we employ nearly 6,000 people across 30 facilities in the UK, Italy, Germany, the Netherlands, Ireland, Slovakia, the Czech Republic, and Canada. Valeo Foods Group is owned by Bain Capital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250502453540/en/
Contacts
Robert Brown
rbrown@reputation-inc.com
+353 (0) 85 725 2626
Reputation Inc
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom